Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. (Q52884682)

9 May 2018

title

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. (English)

1 reference

9 May 2018

main subject

chronic myeloid leukemia

0 references

1 reference

2

1 reference

9 May 2018

Tristan Mirault

10

1 reference

9 May 2018

author name string

T D Kim

1

1 reference

9 May 2018

M Schwarz

3

1 reference

9 May 2018

P Grille

4

1 reference

9 May 2018

F E Nicolini

5

1 reference

9 May 2018

G Rosti

6

1 reference

9 May 2018

L Levato

7

1 reference

9 May 2018

F J Giles

8

1 reference

9 May 2018

H Dombret

9

1 reference

9 May 2018

H Labussière

11

1 reference

9 May 2018

R Lindhorst

12

1 reference

9 May 2018

W Haverkamp

13

1 reference

9 May 2018

I Buschmann

14

1 reference

9 May 2018

B Dörken

15

1 reference

9 May 2018

P D le Coutre

16

1 reference

9 May 2018

publication date

5 March 2013

1 reference

9 May 2018

published in

Leukemia

1 reference

9 May 2018

volume

27

1 reference

9 May 2018

issue

6

1 reference

9 May 2018

page(s)

1316-1321

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1038/leu.2013.70

exact match

0 references

cites work

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotini

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascul

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Severe peripheral arterial disease during nilotinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Cardiotoxicity induced by tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Hypolipemiant besides antileukemic effect of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Imatinib attenuates diabetes-associated atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

The peripheral arterial disease study (PERART/ARTPER): prevalence and risk factors in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

7 January 2021

Nilotinib-associated vascular events

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

7 January 2021

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

7 January 2021

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

7 January 2021

Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.70

7 January 2021

Identifiers

DOI

10.1038/LEU.2013.70

1 reference

9 May 2018

PubMed ID

23459449

1 reference

9 May 2018